JP7280823B2 - 非小細胞肺癌患者由来のエクソソームｒｎａ及び無細胞ｄｎａを使用して血漿中の変異を検出するための方法と組成物 - Google Patents

非小細胞肺癌患者由来のエクソソームｒｎａ及び無細胞ｄｎａを使用して血漿中の変異を検出するための方法と組成物 Download PDF

Info

Publication number
JP7280823B2
JP7280823B2 JP2019528833A JP2019528833A JP7280823B2 JP 7280823 B2 JP7280823 B2 JP 7280823B2 JP 2019528833 A JP2019528833 A JP 2019528833A JP 2019528833 A JP2019528833 A JP 2019528833A JP 7280823 B2 JP7280823 B2 JP 7280823B2
Authority
JP
Japan
Prior art keywords
nucleic acid
exon
mutation
methods
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019528833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536456A5 (cg-RX-API-DMAC7.html
JP2019536456A (ja
Inventor
カール オロフ スコーグ ヨーアン
カステラノス－リザルドス エレナ
タディゴトラ バシシュ
グリム ドミニク
チャン シュアン
ユー ウェイ
Original Assignee
エクソサム ダイアグノスティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクソサム ダイアグノスティクス，インコーポレイティド filed Critical エクソサム ダイアグノスティクス，インコーポレイティド
Publication of JP2019536456A publication Critical patent/JP2019536456A/ja
Publication of JP2019536456A5 publication Critical patent/JP2019536456A5/ja
Application granted granted Critical
Publication of JP7280823B2 publication Critical patent/JP7280823B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019528833A 2016-11-30 2017-11-17 非小細胞肺癌患者由来のエクソソームｒｎａ及び無細胞ｄｎａを使用して血漿中の変異を検出するための方法と組成物 Active JP7280823B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428059P 2016-11-30 2016-11-30
US62/428,059 2016-11-30
PCT/US2017/062370 WO2018102162A1 (en) 2016-11-30 2017-11-17 Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients

Publications (3)

Publication Number Publication Date
JP2019536456A JP2019536456A (ja) 2019-12-19
JP2019536456A5 JP2019536456A5 (cg-RX-API-DMAC7.html) 2021-01-07
JP7280823B2 true JP7280823B2 (ja) 2023-05-24

Family

ID=60766137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528833A Active JP7280823B2 (ja) 2016-11-30 2017-11-17 非小細胞肺癌患者由来のエクソソームｒｎａ及び無細胞ｄｎａを使用して血漿中の変異を検出するための方法と組成物

Country Status (7)

Country Link
US (1) US11427864B2 (cg-RX-API-DMAC7.html)
EP (1) EP3548635B1 (cg-RX-API-DMAC7.html)
JP (1) JP7280823B2 (cg-RX-API-DMAC7.html)
CN (1) CN110446790B (cg-RX-API-DMAC7.html)
AU (1) AU2017366813B2 (cg-RX-API-DMAC7.html)
CA (1) CA3044056A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018102162A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11427864B2 (en) 2016-11-30 2022-08-30 Exosome Diagnostics, Inc. Methods and compositions to detect mutations in plasma using exosomal RNA and cell free DNA from non-small cell lung cancer patients
CN111465707A (zh) * 2017-11-17 2020-07-28 简·探针公司 用于检测C1orf43核酸的组合物和方法
CN108707671A (zh) * 2018-06-12 2018-10-26 上海浦美生物医药科技有限公司 一种用于血液egfr c797s突变检测的引物探针组合物和试剂盒
CN109207595A (zh) * 2018-10-07 2019-01-15 浙江数问生物技术有限公司 一种人egfr基因t790m突变检测试剂盒及其检测方法
EP3931351B1 (en) * 2019-03-01 2024-09-11 Mercy Bioanalytics, Inc. Method for target entity detection using ligase
CN110749734A (zh) * 2019-12-06 2020-02-04 四川大学华西医院 Gtf2i自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN111733158B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0003599表达的siRNA及其应用
CN111500640B (zh) * 2020-04-17 2021-09-10 四川省人民医院 Rp疾病模型的构建方法以及培育方法
CN111748624B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 用于预测肝癌是否复发的生物标志物
CN111676290B (zh) * 2020-07-02 2021-03-02 王伟佳 一种急性髓系白血病诱导分化治疗耐药的分子标志物及其应用
CN111690752A (zh) * 2020-07-16 2020-09-22 重庆浦洛通基因医学研究院有限公司 一种检测人类egfr基因突变的试剂盒及其方法
CN112410335B (zh) * 2020-11-03 2022-10-04 安徽大学 一种阻止lactb2表达来抑制非小细胞肺癌增殖生长的应用
CN112501292B (zh) * 2020-11-09 2022-12-02 中国人民解放军海军军医大学 cFAM210A在制备肝癌诊断或术后预测试剂盒以及药物中的应用
CN114480607B (zh) * 2020-11-12 2024-04-30 上海昂朴生物科技有限公司 用于检测gipc1基因5’-utr区域cgg扩增次数的pcr检测试剂盒及应用
CN112375810A (zh) * 2020-11-16 2021-02-19 北京大学人民医院 GnT-II基因下调表达作为肝癌预后标志物中的应用
CN112370527B (zh) * 2020-12-02 2022-11-01 成都医学院第一附属医院 Dnajc19基因作为靶点在制备治疗非小细胞肺癌药物中的应用
CN112481234B (zh) * 2020-12-03 2023-09-22 重庆工业职业技术学院 一种焦磷酸酶突变体合成核酸糖类似物及其应用
CN112795652A (zh) * 2021-02-02 2021-05-14 中国科学院合肥物质科学研究院 环形RNAcircURI1在制备胃癌生物标志物的应用及其试剂盒
US20240301413A1 (en) * 2021-03-11 2024-09-12 The Children's Hospital Of Philadelphia Compositions and methods useful for the treatment of bone marrow failure diseases associated with ribosomopathies
CN113373206A (zh) * 2021-08-03 2021-09-10 远辰生物科技(苏州)有限公司 一种egfr基因突变检测体系及其试剂盒
CN113774135B (zh) * 2021-09-17 2024-03-08 广东省人民医院 一组用于预测高级别浆液性卵巢癌预后的标志物及其应用
CN113549697B (zh) * 2021-09-23 2022-03-01 广州医科大学附属肿瘤医院 一种胃癌热化疗敏感标志物及其应用
CN113913333B (zh) * 2021-10-20 2022-09-02 南京世和基因生物技术股份有限公司 一种肺癌诊断标志物及用途
CN114231529B (zh) * 2021-11-17 2023-08-01 中国科学院昆明动物研究所 一种人pkmyt1ar基因及其应用
CN114934048B (zh) * 2022-02-22 2023-09-26 浙大城市学院 一种用于肿瘤治疗靶点和诊断生物标志物的circMTMR14及试剂盒和应用
US20250179500A1 (en) * 2022-03-08 2025-06-05 Korea Advanced Institute Of Science And Technology Pharmaceutical composition comprising setmar inhibitor for preventing or treating cancer
CN114672564B (zh) * 2022-03-31 2025-06-13 郑州颐和医院 Tmod3和/或adsl在非小细胞癌中的应用
CN114592006A (zh) * 2022-04-29 2022-06-07 昆明理工大学 Memo1基因的新用途
CN114839375B (zh) * 2022-05-23 2025-07-25 中国药科大学 与肺癌相关的尿液微囊泡蛋白及其应用
CN114703287B (zh) * 2022-06-06 2022-08-12 江苏省肿瘤医院 CXorf56基因在治疗三阴性乳腺癌中的应用
CN114703288B (zh) * 2022-06-06 2022-09-13 珠海圣美生物诊断技术有限公司 用于扩增EGFR-T790M基因变异的blocker探针、引物组及其应用
CN115896262B (zh) * 2022-07-12 2025-05-30 重庆医科大学附属儿童医院 一种神经嵴疾病的诊断标志物及其应用
CN115877004B (zh) * 2022-08-09 2024-12-20 重庆大学 一种taok3抑制剂以及taok3及其抑制剂在调控天然免疫系统中的应用
CN115948532A (zh) * 2022-08-17 2023-04-11 湖南圣洲生物科技有限公司 基于数字pcr技术的sma检测试剂盒
CN115354079A (zh) * 2022-09-05 2022-11-18 复旦大学附属中山医院 一种用于检测egfr靶向药物治疗适用性的试剂盒
EP4590861A1 (en) * 2022-09-21 2025-07-30 Zephyr AI, Inc. Apparatus and methods for determining sensitivity to osimertinib
CN115595372B (zh) * 2022-12-16 2023-03-14 南京世和基因生物技术股份有限公司 一种血浆游离dna来源的甲基化检测方法、肺癌诊断标志物以及试剂盒
CN116240275A (zh) * 2023-03-01 2023-06-09 申联生物医药（上海）股份有限公司 一种哺乳动物通用的rna内参基因及其引物和应用
CN116751873B (zh) * 2023-06-26 2025-04-08 宁夏大学 与牛十字部高相关的snp位点及应用
CN117491636A (zh) * 2023-11-21 2024-02-02 郑州大学 一种用于肺癌诊断的生物标志物及其应用
CN118599905A (zh) * 2024-02-21 2024-09-06 湖北文理学院 Tm9sf1在用于抑制fen1进入细胞核中的应用
CN118584109B (zh) * 2024-03-26 2025-08-15 首都医科大学附属北京胸科医院 一种筛选耐药性肺癌的生物标志物
CN118910268B (zh) * 2024-06-26 2025-12-05 中国农业大学 一种与鸡六周龄体重性状相关的snp标记及其应用
CN118813812B (zh) * 2024-06-26 2025-12-05 中国农业大学 一种与鸡不同周龄胸深相关的snp分子标记及应用
CN119709991B (zh) * 2025-02-28 2025-06-24 华中科技大学同济医学院附属同济医院 芳基硫酸酯酶k在制备预防、延缓或治疗慢性阻塞性肺疾病药物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639611A (en) 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
CA2218875C (en) 1991-07-23 2000-11-07 The Research Foundation Of State University Of New York Improvements in the in situ pcr
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5556773A (en) 1993-08-06 1996-09-17 Yourno; Joseph Method and apparatus for nested polymerase chain reaction (PCR) with single closed reaction tubes
AU735416B2 (en) 1996-11-06 2001-07-05 Sequenom, Inc. Dna diagnostics based on mass spectrometry
US6994960B1 (en) 1997-05-28 2006-02-07 The Walter And Eliza Hall Institute Of Medical Research Nucleic acid diagnostics based on mass spectrometry or mass separation and base specific cleavage
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
FR2788780B1 (fr) 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
US6277607B1 (en) * 1999-05-24 2001-08-21 Sanjay Tyagi High specificity primers, amplification methods and kits
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
US6913879B1 (en) 2000-07-10 2005-07-05 Telechem International Inc. Microarray method of genotyping multiple samples at multiple LOCI
US6696271B2 (en) 2001-08-23 2004-02-24 The Regents Of The University Of California Frozen tissue microarray technology for analysis of RNA, DNA, and proteins
WO2003023065A1 (en) 2001-09-06 2003-03-20 Syngenta Participations Ag Dna methylation patterns
ES2431944T3 (es) 2002-06-26 2013-11-28 Cold Spring Harbor Laboratory Métodos para determinar los perfiles de metilación
WO2004020667A1 (en) 2002-09-02 2004-03-11 Pamgene B.V. Novel integrated microarray analysis
US7141371B2 (en) 2002-09-06 2006-11-28 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for detecting and localizing DNA mutations by microarray
US20080187923A1 (en) 2005-04-15 2008-08-07 Cedars-Sinai Medical Center Flow-Cytometric Heteroduplex Analysis for Detection of Genetic Alterations
AU2007293280A1 (en) * 2006-09-07 2008-03-13 Astrazeneca Ab Method for evaluating patients for treatment with drugs targeting RET receptor tyrosine kinase
CN101622350A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
US20090104120A1 (en) * 2007-09-25 2009-04-23 The Regents Of The University Of Michigan Dlx1 cancer markers
KR20100127768A (ko) * 2008-02-01 2010-12-06 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
US20160041153A1 (en) * 2008-11-12 2016-02-11 Kirk Brown Biomarker compositions and markers
WO2012135844A2 (en) * 2011-04-01 2012-10-04 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
EP3499212B1 (en) 2013-01-03 2020-08-12 Exosome Diagnostics, Inc. Methods for isolating microvesicles
EP3421613B1 (en) * 2013-03-15 2020-08-19 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
WO2014193999A2 (en) * 2013-05-28 2014-12-04 Caris Science, Inc. Biomarker methods and compositions
US20150132256A1 (en) * 2013-10-19 2015-05-14 Trovagene, Inc. Detecting and monitoring mutations in histiocytosis
WO2015066485A2 (en) * 2013-10-31 2015-05-07 The Children's Hospital Of Philadelphia Mitochondrial disease genetic diagnostics
WO2015153732A2 (en) * 2014-04-01 2015-10-08 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
CA2954576C (en) 2014-07-09 2020-08-11 Daniel ENDERLE Methods for isolating microvesicles and extracting nucleic acids from biological samples
US11427864B2 (en) 2016-11-30 2022-08-30 Exosome Diagnostics, Inc. Methods and compositions to detect mutations in plasma using exosomal RNA and cell free DNA from non-small cell lung cancer patients

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
313 Development of a one-step isolation platform for exosomal RNA and circulating cell-free DNA from cancer plasma samples，European Journal of Cancer，2014年，vol.50, suppl.6，p.102,
Clin Cancer Res，2009年，vol.15, no.8，p.2630-2636
Clinical Chemistry，2003年，vol.49, no.10，p.1624-1631
European Respiratory Journal，2012年，vol.40, Issue Suppl 56，Abstract No: 7263, Publication No: 1397
Journal of Immunological Methods，2007年，vol.321，p.135-141
Molecular Cancer Therapeutics，2015年，vol.14, issue 12, supplement 2，Abatract B136
The Journal of Molecular Diagnostics，2013年，vol.15, no.1，p.62-69

Also Published As

Publication number Publication date
AU2017366813A1 (en) 2019-06-13
CN110446790B (zh) 2023-03-31
EP3548635B1 (en) 2021-04-28
US11427864B2 (en) 2022-08-30
AU2017366813B2 (en) 2023-04-20
WO2018102162A1 (en) 2018-06-07
US20190376128A1 (en) 2019-12-12
JP2019536456A (ja) 2019-12-19
CA3044056A1 (en) 2018-06-07
CN110446790A (zh) 2019-11-12
EP3548635A1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
JP7280823B2 (ja) 非小細胞肺癌患者由来のエクソソームｒｎａ及び無細胞ｄｎａを使用して血漿中の変異を検出するための方法と組成物
US20190093172A1 (en) Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer
US12139766B2 (en) Methods and kits comprising gene signatures for stratifying breast cancer patients
US10793914B2 (en) Cancer-related biological materials in microvesicles
KR102080161B1 (ko) 개인 맞춤형 의료를 위한 유전자 패널, 그를 구성하는 방법, 및 그를 이용한 개인 맞춤형 치료 방법
US20190360051A1 (en) Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
US20180371550A1 (en) Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
US20230112964A1 (en) Assessment of melanoma therapy response
WO2019008412A1 (en) USE OF BLOOD GENE EXPRESSION ANALYSIS FOR CANCER CARE
WO2019008414A1 (en) GENE EXPRESSION ANALYSIS BASED ON EXOSOMES FOR THE CARE OF CANCER
WO2019008415A1 (en) EXOSOMED AND PBMC GENE EXPRESSION ANALYSIS FOR CANCER CARE
US20240218457A1 (en) Method for diagnosing active tuberculosis and progression to active tuberculosis
US20230143295A1 (en) Methods and kits for determining the risk of breast cancer recurrence
EP4568962A2 (en) Methods for modulating rna splicing
KIAA1522 et al. TPRG1L NOLC1
NANOG et al. EC Common type Transport KIAA1549, MBD5, MYO5B, RAB11A, RAB11FIP1, RAB11FIP2, RAB11FIP3, RAB11FIP4, RAB11FIP5, REPS1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230512

R150 Certificate of patent or registration of utility model

Ref document number: 7280823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150